Study of glofitamab plus chemo for relapsed DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of drugs—glofitamab, gemcitabine, and oxaliplatin—for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The goal is to see if this treatment works safely and effectively for those who have already tried at least one other therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with diffuse large B-cell lymphoma (DLBCL), a specific type of non-Hodgkin lymphoma.
- Your cancer either came back after a previous treatment or did not respond well enough. If it came back, it must have been at least 6 months after finishing your last treatment.
- You have already tried at least one prior treatment for your lymphoma.
- If you have only tried one prior treatment, you must not be a candidate for a stem cell transplant (high-dose chemo with a stem cell rescue).
- You must have at least one tumor that can be seen on a CT scan (a lymph node at least 1.5 cm wide or a tumor elsewhere at least 1 cm wide).
- You must be generally active or able to carry on with daily activities (ECOG score of 0, 1, or 2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
This trial tests a combination of two drugs (glofitamab, gemcitabine, oxaliplatin) followed by liso-cel (a CAR T-cell therapy) for people with large B-cell lymphoma who have only had one prior treatment and whose lymphoma came back. The goal is to see if this approach works better than standard treatments.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
This trial tests combining radiation therapy with a drug called glofitamab (a type of immunotherapy) for patients whose diffuse large B-cell lymphoma (DLBCL) has returned or stopped responding to previous treatments. The goal is to see if adding radiation to this newer drug helps control the cancer better.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.